12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Poniard, Verastem preclinical data

In a mouse xenograft model of TNBC, VS-4718 significantly reduced primary (p=0.05) and secondary (p=0.0015) cancer stem cells in tumors vs. vehicle-treated controls. In vitro, VS-4718 reduced the percent...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >